![[Feedback]](/icons/banner/feedbackACT.gif){kind=icon}
![[For Subscribers]](/icons/banner/subscriberACT.gif){kind=icon}
![[Archive]](/icons/banner/archiveACT.gif){kind=icon}
![[Search]](/icons/banner/searchACT.gif){kind=icon}
![[Contents]](/icons/banner/tocACT.gif){kind=icon}
|
|
|
|
|
||
CA Broomfield, DM Maxwell, RP Solana, CA Castro, AV Finger and DE Lenz
U.S. Army Medical Research Institute of Chemical Defense, Aberdeen Proving Ground, Maryland.
Butyrylcholinesterase (BuChE) was examined as an in vivo exogenous scavenger for highly toxic organophosphorus (OP) poisons. Protection studies with equine BuChE were carried out in rhesus monkeys trained to perform a Serial Probe Recognition task. The pharmacokinetics of equine BuChE administered i.v. in rhesus monkeys revealed an elimination T1/2 of approximately 620 hr. Animals given 503 nmol of BuChE i.v. and then challenged with 220 to 260 nmol of soman (two LD50; a lethal dose in untreated animals) all survived with no clinical signs of OP poisoning. Serial Probe Recognition performance was depressed after enzyme administration and at 1 hr postsoman. However, all monkeys performed the task at base-line levels at 8 hr after soman and throughout the remainder of the experimental period. Two different monkeys each were given two doses of sarin, 183 nmol/dose (one LD50) after 460 nmol of BuChE. No signs were observed. A third group of monkeys given 253 or 340 nmol (three and four LD50, respectively) of soman after 460 nmol of BuChE required 1 mg/kg of atropine i.v. 10 min postsoman, but recovered completely within 24 hr. Our results indicate that BuChE has the required properties to function as a biological scavenger to protect against the pharmacological and behavioral toxicity of OP poisons.
This article has been cited by other articles:
|
|
 |
|
  M. Guven, M. Sungur, and B. Eser The effect of plasmapheresis on plasma cholinesterase levels in a patient with organophosphate poisoning Human and Experimental Toxicology, July 1, 2004; 23(7): 365 - 368. [Abstract] [PDF]
|
|
|
|
 |
|
 Y. Nicolet, O. Lockridge, P. Masson, J. C. Fontecilla-Camps, and F. Nachon Crystal Structure of Human Butyrylcholinesterase and of Its Complexes with Substrate and Products J. Biol. Chem., October 17, 2003; 278(42): 41141 - 41147. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. G. Duysen, C. F. Bartels, and O. Lockridge Wild-Type and A328W Mutant Human Butyrylcholinesterase Tetramers Expressed in Chinese Hamster Ovary Cells Have a 16-Hour Half-Life in the Circulation and Protect Mice from Cocaine Toxicity J. Pharmacol. Exp. Ther., August 1, 2002; 302(2): 751 - 758. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. N. Carmona, R. A. Jufer, S. R. Goldberg, D. A. Gorelick, N. H. Greig, Q.-S. Yu, E. J. Cone, and C. W. Schindler Butyrylcholinesterase Accelerates Cocaine Metabolism: In Vitro and In Vivo Effects in Nonhuman Primates and Humans Drug Metab. Dispos., March 1, 2000; 28(3): 367 - 371. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Saxena, Y. Ashani, L. Raveh, D. Stevenson, T. Patel, and B. P. Doctor Role of Oligosaccharides in the Pharmacokinetics of Tissue-Derived and Genetically Engineered Cholinesterases Mol. Pharmacol., January 1, 1998; 53(1): 112 - 122. [Abstract] [Full Text]
|
|
 |
 |
 |
|
 |
 |
 |
